ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.33
-0.81%
US Tech 100
18,077.60
0.27%
S&P 500
5,268.56
-0.17%
US Dollar vs CAD
1.3627
0.05%
Bitcoin
69,289.26
2.27%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Arcus Biosciences Inc (RCUS)

  7. Arcus Biosciences Inc (RCUS) News

RCUS

Arcus Biosciences (RCUS)

Arcus Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:RCUS
DateTimeSourceHeadlineSymbolCompany
06/03/20247:18AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:RCUSArcus Biosciences Inc
06/02/20247:00AMBusiness WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerNYSE:RCUSArcus Biosciences Inc
06/02/20247:00AMBusiness WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerNYSE:RCUSArcus Biosciences Inc
06/01/20247:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNYSE:RCUSArcus Biosciences Inc
06/01/20247:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNYSE:RCUSArcus Biosciences Inc
05/24/20243:35PMBusiness WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
05/23/20243:59PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:RCUSArcus Biosciences Inc
05/09/20243:35PMBusiness WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
05/08/20243:08PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:RCUSArcus Biosciences Inc
05/08/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:RCUSArcus Biosciences Inc
05/08/20243:02PMBusiness WireArcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline UpdateNYSE:RCUSArcus Biosciences Inc
05/02/20243:05PMBusiness WireArcus Biosciences to Participate in the Bank of America Healthcare Conference 2024NYSE:RCUSArcus Biosciences Inc
04/24/20243:00PMBusiness WireArcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual MeetingNYSE:RCUSArcus Biosciences Inc
04/23/20243:05PMBusiness WireArcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline UpdateNYSE:RCUSArcus Biosciences Inc
04/09/20243:35PMBusiness WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
03/26/20243:35PMBusiness WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
03/11/20243:35PMBusiness WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
02/28/20243:05PMBusiness WireArcus Biosciences to Participate in Two Upcoming Investor ConferencesNYSE:RCUSArcus Biosciences Inc
02/27/20243:35PMBusiness WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
02/21/20243:53PMEdgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNYSE:RCUSArcus Biosciences Inc
02/21/20243:32PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:RCUSArcus Biosciences Inc
02/21/20243:08PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:RCUSArcus Biosciences Inc
02/21/20243:05PMBusiness WireArcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline UpdateNYSE:RCUSArcus Biosciences Inc
02/09/20243:35PMBusiness WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
02/07/20245:58PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:RCUSArcus Biosciences Inc
02/07/20244:00PMBusiness WireArcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline UpdatesNYSE:RCUSArcus Biosciences Inc
01/30/20247:17AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:RCUSArcus Biosciences Inc
01/30/20245:25AMIH Market NewsArcus Biosciences Stock Jumps 20% on $320M Gilead Investment, Super Micro Surpasses Forecasts, and More NewsNYSE:RCUSArcus Biosciences Inc
01/29/20244:00PMBusiness WireGilead and Arcus Announce Amended Collaboration and Equity InvestmentNYSE:RCUSArcus Biosciences Inc
01/29/20244:00PMBusiness WireGilead and Arcus Announce Amended Collaboration and Equity InvestmentNYSE:RCUSArcus Biosciences Inc
 Showing the most relevant articles for your search:NYSE:RCUS

Your Recent History

AMEX
FFLG
Fidelity Fundamental Lar...
BIT
P1KKR3
BNP Paribas Issuance
LSE
FO99
Hsbc Bk.24
TG
A3LPB7
Accor
LSE
SR12
Lon &quad Ho.32
NASDAQ
FAZIFX
Stonebridge Preferred In...
LSE
0HX1
Eagle Football
NASDAQ
LNBB
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved